Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some specific infection/bleeding/arrhythmia and second malignancy warnings are supported by the provided FDA label sections, but multiple claims are marked as absent or unverifiable, including several detailed symptom-specific and clinical-counseling nuances and broad/speculative statements.
Category Scores
Accurate Statements
Calquence (acalabrutinib) can increase the risk of serious and sometimes fatal infections.
Supported by 5.1 Serious and Opportunistic Infections
Clinicians are advised to monitor for signs of infection during Calquence treatment.
Supported by 5.1 Serious and Opportunistic Infections
Patients should report fever or symptoms that suggest infection promptly while taking Calquence.
Supported by 17 PATIENT COUNSELING INFORMATION (Serious and Opportunistic Infections)
Calquence can increase bleeding risk.
Supported by 5.2 Hemorrhage
Calquence warnings advise caution in patients taking medicines that affect bleeding (for example, anticoagulants or antiplatelet drugs).
Supported by 5.2 Hemorrhage
Patients should seek medical care for unusual bleeding while taking Calquence.
Supported by 17 PATIENT COUNSELING INFORMATION (Hemorrhage)
Calquence may cause atrial fibrillation.
Supported by 5.5 Cardiac Arrhythmias
Calquence may cause atrial flutter.
Supported by 5.5 Cardiac Arrhythmias
The prescribing information advises monitoring for symptoms such as palpitations, dizziness, shortness of breath, or fainting.
Supported by 5.5 Cardiac Arrhythmias and 17 PATIENT COUNSELING INFORMATION (Cardiac Arrhythmias)
The prescribing information includes warnings/precautions for the development of malignancies, including secondary cancers, during Calquence treatment.
Supported by 5.4 Second Primary Malignancies and 17 PATIENT COUNSELING INFORMATION (Second Primary Malignancies)
Unsupported Statements
Clinicians are advised to evaluate patients for infection before starting Calquence.
Marked absent from the label in the provided claim evaluation; no FDA label section provided to support this instruction.
Calquence warnings advise caution in patients with bleeding disorders.
Marked absent from the label in the provided claim evaluation; no FDA label section provided to support this specific precaution.
Calquence warnings include seeking medical care for blood in stool or urine.
Marked absent from the label in the provided claim evaluation; no FDA label section provided to support this specific symptom counseling.
Calquence warnings include seeking medical care for severe bruising.
Marked absent from the label in the provided claim evaluation; no FDA label section provided to support this specific symptom counseling.
Patients should be evaluated for new symptoms or concerning findings that could suggest a cancer-related problem during Calquence treatment.
Marked absent from the label in the provided claim evaluation; no FDA label section provided to support this specific phrasing/instruction.
Calquence has warnings/precautions addressing other clinically significant risks and lab abnormalities reported with acalabrutinib and the BTK inhibitor class.
Cannot verify from the provided label sections; no FDA label citation provided to support this broad characterization.
The full official “Warnings and Precautions” text for Calquence is available in the Calquence FDA label.
Non-evaluative/verification statement; no label section citation provided in the input to treat as a label-supported prescribing claim.
The full official “Warnings and Precautions” text for Calquence is available in the Calquence UK summary of product characteristics (SmPC).
Non-evaluative/verification statement; not supported by any provided FDA-label citation.
Boxed/major precautions in BTK inhibitors commonly matter most for patients with a history of recurrent infections or frequent healthcare exposure.
Marked absent/unverifiable; no FDA-label citation provided and phrasing appears speculative rather than Calquence-label-specific.
Boxed/major precautions in BTK inhibitors commonly matter most for patients with prior bleeding or concurrent blood-thinning therapy.
Marked absent/unverifiable; no FDA-label citation provided and phrasing appears speculative rather than Calquence-label-specific.
Boxed/major precautions in BTK inhibitors commonly matter most for patients with prior atrial fibrillation/flutter or cardiovascular disease.
Marked absent/unverifiable; no FDA-label citation provided and phrasing appears speculative rather than Calquence-label-specific.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No claim addressed the label instruction to consider prophylaxis in patients at increased risk for opportunistic infections (and prompt treatment), despite discussing serious/fatal infections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant counseling details are not supported/verified (e.g., specific bleeding-in-stool/urine and bruising instructions; specific pre-treatment infection evaluation; broad speculative BTK-population statements). Supported core warnings are present for serious infections, hemorrhage risk (including antithrombotics), arrhythmia monitoring, and second malignancies.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are marked absent from the label or not verifiable from the provided FDA label excerpts, including specific symptom-counseling and speculative generalizations about BTK inhibitor boxed/major precautions.
Suggested Improvement
Restrict claims to label-supported language within provided FDA sections (5.1, 5.2, 5.4, 5.5, and 17) or provide the missing FDA label citations for the unsupported/specific counseling and broad BTK-class statements.